4,5-二溴-3-甲基噻吩-2-甲酸甲酯 | 648412-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4,5-二溴-3-甲基噻吩-2-甲酸甲酯
• 英文名称: methyl 4,5-dibromo-3-methylthiophene-2-carboxylate
• CAS: 648412-53-7
• 化学式: C₇H₆Br₂O₂S
• 分子量: 313.997
• InChiKey: WQCQDITXZPVXGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4,5-二溴-3-甲基噻吩-2-甲酸甲酯 在 lithium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 、 三氟乙酸 、 过氧化苯甲酰 作用下， 以 1,4-二氧六环 、 甲醇 、 四氯化碳 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 3-(2-carboxy-4,5-dibromothiophen-3-yl-methyl)-5-methylpyrimidine-2,4-dione
  参考文献：
  名称：

  Synthesis and Pharmacological Characterization of N³-Substituted Willardiine Derivatives:  Role of the Substituent at the 5-Position of the Uracil Ring in the Development of Highly Potent and Selective GLU_K5 Kainate Receptor Antagonists

  摘要：

  Some N-3-substituted analogues of willardiine such as 11 and 13 are selective kainate receptor antagonists. In an attempt to improve the potency and selectivity for kainate receptors, a range of analogues of 11 and 13 were synthesized with 5-substituents on the uracil ring. An X-ray crystal structure of the 5-methyl analogue of 13 bound to GLU(K5) revealed that there was allowed volume around the 4- and 5-positions of the thiophene ring, and therefore the 4,5-dibromo and 5-phenyl (67) analogues were synthesized. Compound 67 (ACET) demonstrated low nanomolar antagonist potency on native and recombinant GLU(K5)-containing kainate receptors (K-B values of 7 +/- 1 and 5 +/- 1 nM for antagonism of recombinant human GLU(K5) and GLU(K5)/GLU(K2), respectively) but displayed IC50 values > 100 mu M for antagonism of GLU(A2), GLU(K6), or GLU(K6)/GLU(K2).

  DOI：

  10.1021/jm061041u
• 作为产物：
  描述：

  3-甲基噻吩-2-羧酸 在 硫酸 、 溴 、 溶剂黄146 作用下， 反应 18.0h， 生成 4,5-二溴-3-甲基噻吩-2-甲酸甲酯
  参考文献：
  名称：

  Synthesis and Pharmacological Characterization of N³-Substituted Willardiine Derivatives:  Role of the Substituent at the 5-Position of the Uracil Ring in the Development of Highly Potent and Selective GLU_K5 Kainate Receptor Antagonists

  摘要：

  Some N-3-substituted analogues of willardiine such as 11 and 13 are selective kainate receptor antagonists. In an attempt to improve the potency and selectivity for kainate receptors, a range of analogues of 11 and 13 were synthesized with 5-substituents on the uracil ring. An X-ray crystal structure of the 5-methyl analogue of 13 bound to GLU(K5) revealed that there was allowed volume around the 4- and 5-positions of the thiophene ring, and therefore the 4,5-dibromo and 5-phenyl (67) analogues were synthesized. Compound 67 (ACET) demonstrated low nanomolar antagonist potency on native and recombinant GLU(K5)-containing kainate receptors (K-B values of 7 +/- 1 and 5 +/- 1 nM for antagonism of recombinant human GLU(K5) and GLU(K5)/GLU(K2), respectively) but displayed IC50 values > 100 mu M for antagonism of GLU(A2), GLU(K6), or GLU(K6)/GLU(K2).

  DOI：

  10.1021/jm061041u

文献信息

• 5-Membered heterocyclic compound
  申请人：Nishida Haruyuki

  公开号：US20090156642A1

  公开（公告）日：2009-06-18

  The present invention provides 5-membered heterocycle compounds represented by the following general formula (I): The present compounds have a superior acid secretion inhibitory effect, and shows an antiulcer activity and the like.

  本发明提供了以下通式(I)表示的5元杂环化合物： 本化合物具有优异的抑制胃酸分泌效果，并显示出抗溃疡活性等。
• Heterobicyclic pyrazole derivatives as kinase inhibitors
  申请人：Tonani Roberto

  公开号：US20060160874A1

  公开（公告）日：2006-07-20

  Bicyclo-pyrazoles of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了如规范中定义的化学式（I）的双环吡唑及其药用盐，其制备方法以及包含它们的药物组合物；本发明的化合物在治疗中可能有用，用于治疗与异常蛋白激酶活性相关的疾病，如癌症。
• [EN] HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE PYRAZOLE HETEROBICYCLIQUES UTILISES COMME INHIBITEURS DE KINASE
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2004007504A1

  公开（公告）日：2004-01-22

  Bicyclo-pyrazoles of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了规范中定义的化学式(I)的双环吡唑及其药用盐，其制备方法和包含它们的药物组合物；发明中的化合物可能在治疗中对治疗与蛋白激酶活性失调相关的疾病，如癌症，具有用处。
• [EN] SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF<br/>[FR] THIOPHÈNE CARBOXAMIDES SUBSTITUÉS, ACIDES THIOPHÈNE CARBOXYLIQUES ET LEURS DÉRIVÉS
  申请人：BAYER AG

  公开号：WO2021123051A1

  公开（公告）日：2021-06-24

  The present disclosure relates to substituted thiophene carboxamides derivatives of formula (I) adn (II), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.

  本公开涉及公式(I)和(II)的取代噻吩羧酰胺衍生物，其用于控制植物病原微生物以及包含它们的组合物。
• Novel thienopyridine compounds, and methods of use thereof
  申请人：Turtle D. Eric

  公开号：US20060199836A1

  公开（公告）日：2006-09-07

  The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).

  本发明涉及一种能够调节缺氧诱导因子（HIF）稳定性和/或活性的新化合物。